ZFIN ID: ZDB-PUB-181004-3
Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator
Hwang, S., Mruk, K., Rahighi, S., Raub, A.G., Chen, C.H., Dorn, L.E., Horikoshi, N., Wakatsuki, S., Chen, J.K., Mochly-Rosen, D.
Date: 2018
Source: Nature communications   9: 4045 (Journal)
Registered Authors: Chen, James K., Mruk, Karen
Keywords: none
MeSH Terms:
  • Animals
  • Drug Evaluation, Preclinical
  • Enzyme Activation
  • Glucosephosphate Dehydrogenase/genetics
  • Glucosephosphate Dehydrogenase/metabolism*
  • Glucosephosphate Dehydrogenase Deficiency/drug therapy*
  • Glucosephosphate Dehydrogenase Deficiency/genetics
  • Hemolysis/drug effects
  • Humans
  • Indoles/chemistry
  • Indoles/pharmacology
  • Indoles/therapeutic use*
  • Mutation, Missense
  • Oxidative Stress/drug effects
  • Protein Stability
  • Zebrafish
PubMed: 30279493 Full text @ Nat. Commun.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, one of the most common human genetic enzymopathies, is caused by over 160 different point mutations and contributes to the severity of many acute and chronic diseases associated with oxidative stress, including hemolytic anemia and bilirubin-induced neurological damage particularly in newborns. As no medications are available to treat G6PD deficiency, here we seek to identify a small molecule that corrects it. Crystallographic study and mutagenesis analysis identify the structural and functional defect of one common mutant (Canton, R459L). Using high-throughput screening, we subsequently identify AG1, a small molecule that increases the activity of the wild-type, the Canton mutant and several other common G6PD mutants. AG1 reduces oxidative stress in cells and zebrafish. Furthermore, AG1 decreases chloroquine- or diamide-induced oxidative stress in human erythrocytes. Our study suggests that a pharmacological agent, of which AG1 may be a lead, will likely alleviate the challenges associated with G6PD deficiency.